Everyday Health on MSN

SGLT2 inhibitors and IgAN: Can this diabetes drug delay kidney decline?

Explore the potential of SGLT2 inhibitors for IgAN. Learn how these diabetes drugs slow kidney damage progression when added to standard treatment.
European Medical Journal

SGLT2 Inhibitors Linked to Improved Kidney Outcomes in Type 2 Diabetes

SGLT2 inhibitors were linked to better kidney outcomes than GLP-1 receptor agonists in Type 2 diabetes. Learn more about the ...
Medscape

Do Certain Diabetes Medications Increase Depression Risk?

In patients with diabetes, sustained use of GLP-1 receptor agonists is associated with a modestly higher risk for new-onset ...
MedPage Today

Study Questions Need to Hold SGLT2 Inhibitors Before Surgery

Use of SGLT2 inhibitors before emergency surgery was not associated with an increased risk for postoperative diabetic ketoacidosis. The FDA previously issued guidance on withholding SGLT2 inhibitors ...
Healio

SGLT2 inhibitors may slow eGFR decline in autosomal dominant polycystic kidney disease

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibitors vs. other agents were tied to a slower eGFR decline for adults with ADPKD and type 2 diabetes.
The American Journal of Managed Care

SGLT2 Inhibitors Show Protective Effect on Kidneys

SGLT2 inhibitors combat inflammation and slow kidney disease by elevating S-adenosylmethionine (SAM) levels, which suppress inflammatory gene activity through epigenetic modification. The benefits of ...
The American Journal of Managed Care

Meta-Analysis Finds SGLT2 Inhibitors Boost Hemoglobin, Hematocrit in CKD

SGLT2 inhibitors significantly improve hemoglobin and hematocrit levels in CKD patients, enhancing anemia management. The KDIGO 2024 guideline endorses SGLT2 inhibitors for CKD patients, highlighting ...